Free Trial
NASDAQ:VIR

Vir Biotechnology (VIR) Stock Price, News & Analysis

Vir Biotechnology logo
$5.50 +0.07 (+1.29%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$5.50 0.00 (0.00%)
As of 04/17/2025 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vir Biotechnology Stock (NASDAQ:VIR)

Key Stats

Today's Range
$5.34
$5.53
50-Day Range
$5.19
$9.85
52-Week Range
$4.95
$14.45
Volume
713,272 shs
Average Volume
1.34 million shs
Market Capitalization
$754.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.57
Consensus Rating
Moderate Buy

Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

VIR MarketRank™: 

Vir Biotechnology scored higher than 52% of companies evaluated by MarketBeat, and ranked 455th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vir Biotechnology has only been the subject of 4 research reports in the past 90 days.

  • Read more about Vir Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Vir Biotechnology are expected to grow in the coming year, from ($3.92) to ($3.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vir Biotechnology is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vir Biotechnology is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vir Biotechnology has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Vir Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    11.56% of the float of Vir Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Vir Biotechnology has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Vir Biotechnology has recently increased by 28.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vir Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Vir Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.56% of the float of Vir Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Vir Biotechnology has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Vir Biotechnology has recently increased by 28.30%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Vir Biotechnology has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.
  • Search Interest

    Only 3 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $663,525.00 in company stock.

  • Percentage Held by Insiders

    15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vir Biotechnology's insider trading history.
Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

VIR Stock News Headlines

Stock Movers: Moderna, Tesla, Canada Goose
Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
Vir Biotechnology enrolls first patient in ECLIPSE program
See More Headlines

VIR Stock Analysis - Frequently Asked Questions

Vir Biotechnology's stock was trading at $7.34 at the start of the year. Since then, VIR shares have decreased by 25.1% and is now trading at $5.50.
View the best growth stocks for 2025 here
.

Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.09. The firm had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative trailing twelve-month return on equity of 36.71%.
Read the conference call transcript
.

Vir Biotechnology (VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO.

Vir Biotechnology's top institutional investors include Rhumbline Advisers (0.17%), GAMMA Investing LLC (0.03%), Wealth Enhancement Advisory Services LLC (0.01%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Howard Horn, Ann M Hanly, Steven J Rice, Sung Lee, Verneuil Vanina De, Brent Sabatini, Saira Ramasastry, Janet Napolitano and Charles Elliott Sigal.
View institutional ownership trends
.

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V).

Company Calendar

Last Earnings
2/26/2025
Today
4/19/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VIR
Fax
N/A
Employees
580
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.57
High Stock Price Target
$110.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+510.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-615,060,000.00
Net Margins
-678.40%
Pretax Margin
-685.83%

Debt

Sales & Book Value

Annual Sales
$63.71 million
Price / Cash Flow
N/A
Book Value
$11.82 per share
Price / Book
0.47

Miscellaneous

Free Float
116,236,000
Market Cap
$754.29 million
Optionable
Optionable
Beta
1.14
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:VIR) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners